Exiqon

Exiqon has introduced LNA longRNA gapmers, a collection of RNase U-activating antisense oligonucleotides for the specific inhibition of mRNA and long non-coding RNAs in vitro and in vivo.

Title: Methods for Quantification of microRNAs and Small Interfering RNAs
Patent Number: 8,383,344
Filed: June 1, 2009
Lead Inventor: Nana Jacobsen, Exiqon

Exiqon this week launched MiRcury RNA Isolation Kit-Biofluids for extraction of small RNAs from serum, plasma, urine, and other biofluids.

Exiqon has launched a MiRcury RNA isolation kit designed specifically to extract small RNAs, including microRNAs, from serum, plasma, urine, and other biofluids.

NEW YORK (GenomeWeb News) – Danish genomics and molecular diagnostics firm Exiqon today reported that its third-quarter revenues rose 11 percent year over year.

NEW YORK (GenomeWeb News) – Takara Bio will distribute Exiqon's miRCURY LNA products in Asia beginning in January 2013, Exiqon announced today.

Knome has launched an early access program for KnomeClinic, a software suite that medical researchers and clinicians can use to interpret and annotate human genomes.

Exiqon this week launched an online tool for designing Locked Nucleic Acid-enhanced qPCR assays to quantify messenger RNA and non-coding RNA in combination with associated microRNAs.

Exiqon has introduced a new online tool for the design of locked nucleic acid-enhanced qPCR assays for the quantitation of mRNA and non-coding RNAs in combination with associated microRNAs.

Exiqon last week released data from a clinical study showing that its locked nucleic acid technology could be used to detect a microRNA biomarker for colon cancer survival.

Pages

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.